BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

CStone's Sugemalimab Granted NMPA Approval for Esophageal Cancer

Sugemalimab is the world's first anti-PD-L1 monoclonal antibody approved for use in combination with fluorouracil and platinum-based chemotherapy...

December 11, 2023 | News

CRISPR Explores Future of Cell & Gene Therapy at 2024 GenScript Biotech Global Forum

Recently, the world's first CRISPR/Cas9 gene editing therapy received market approval in the UK. This significant achievement comes 11 years after the inve...

December 08, 2023 | News

WuXi Vaccines Passes First GMP Audit by a Global Vaccine Leader

The three-day comprehensive audit covered the CDMO site's drug substance (DS) facility, drug product (DP) facility, QC laboratories, warehouse, and utiliti...

December 07, 2023 | News

Innovent Biologics and Synaffix Expand ADC Collaboration Amid Promising Phase 1 Results

The expanded deal builds on a previous agreement signed in June 2021, under which Innovent is granted to deploy Synaffix's ADC technologies on a targe...

December 07, 2023 | News

FDA Clears CARsgen's CT071 for Relapsed/Refractory Multiple Myeloma

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignan...

December 05, 2023 | News

China Pharma Completes Third-Party Testing for Dry Eye Therapeutic Device

According to a disclosure by the Shanghai Public Health Clinical Center on June 6, 2023, an epidemiological survey of DED showed that approximately 34...

November 30, 2023 | News

Merck Expands Newest Biologics Testing Center in Shanghai

Further develops its biosafety testing laboratories to meet local demand New labs complete 2nd phase of company’s € 29 million...

November 30, 2023 | News

Everest Medicines Gets NMPA Approval for Nefecon® in China for IgA Nephropathy

--Nefecon® is the first approved medicine with an IgAN indication in China-- --The approval marks a new era of IgAN treatment for Chinese patient...

November 27, 2023 | News

DxVx Plans License-In of OVM-200, Launches Clinical Trials in Asia

Final stage in licensing OVM-200 from Oxford Vacmedix in the UK- DxVx plans to proceed its own clinical trials in Asia, including Korea and Chi...

November 27, 2023 | News

China Faces Surge in 'Undiagnosed Pneumonia' Cases Among Children

The outbreak initially surfaced in northern China, prompting the World Health Organization (WHO) to issue an "official request" to ...

November 27, 2023 | News

Simcere and Connect ink exclusive deal for autoimmune drug Rademikibart.

Pursuant to the Agreement, Simcere obtains the exclusive rights in the development, manufacturing, and commercialization of Rademikibart for all indication...

November 24, 2023 | News

BeiGene and Ensem Therapeutics Partner to Advance CDK2 Inhibitor

“We are committed to developing novel molecules with the potential to transform the therapeutic landscape for cancer patients, and this partnership f...

November 23, 2023 | News

WuXi Biologics Achieves Breakthrough Productivity of ~6 g/L/day in Integrated Continuous Process at Pilot Scale

By leveraging WuXiUPTM, WuXi Biologics has completed its first end-to-end continuous drug substance (DS) manufacturing from perfused cell culture...

November 23, 2023 | News

Innovent and AnHeart's Taletrectinib NDA Accepted by China's NMPA

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality me...

November 23, 2023 | News

Stay Connected